1. Biochemistry and Chemical Biology
  2. Immunology and Inflammation
Download icon

In vitro proteasome processing of neo-splicetopes does not predict their presentation in vivo

  1. Gerald Willimsky  Is a corresponding author
  2. Christin Beier
  3. Lena Immisch
  4. Georgios Papafotiou
  5. Vivian Scheuplein
  6. Andrean Goede
  7. Hermann-Georg Holzhütter
  8. Thomas Blankenstein
  9. Peter M Kloetzel  Is a corresponding author
  1. Institute of Immunology (Charité - Universitätsmedizin Berlin) and German Cancer Research Center (DKFZ Heidelberg), Germany
  2. Institute of Biochemistry (Charité - Universitätsmedizin Berlin), Germany
  3. Max-Delbrück Center for Molecular Medicine, Germany
  4. Institut für Physiologie (Charité - Universitätsmedizin Berlin), Germany
  5. Max Delbrück Center for Molecular Medicine in Helmholtz Association, Germany
  6. Charité - Universitätsmedizin Berlin, Germany
Research Article
  • Cited 0
  • Views 442
  • Annotations
Cite this article as: eLife 2021;10:e62019 doi: 10.7554/eLife.62019

Abstract

Proteasome catalyzed peptide splicing (PCPS) of cancer-driving antigens could generate attractive neoepitopes to be targeted by TCR-based adoptive T cell therapy. Based on a spliced peptide prediction algorithm TCRs were generated against putative KRASG12V and RAC2P29L derived neo-splicetopes with high HLA-A*02:01 binding affinity. TCRs generated in mice with a diverse human TCR repertoire specifically recognized the respective target peptides with high efficacy. However, we failed to detect any neo-splicetope specific T cell response when testing the in vivo neo-splicetope generation and obtained no experimental evidence that the putative KRASG12V- and RAC2P29L-derived neo-splicetopes were naturally processed and presented. Furthermore, only the putative RAC2P29L-derived neo-splicetopes was generated by in vitro PCPS. The experiments pose severe questions on the notion that available algorithms or the in vitro PCPS reaction reliably simulate in vivo splicing and argue against the general applicability of an algorithm-driven 'reverse immunology' pipeline for the identification of cancer-specific neo-splicetopes.

Data availability

Additional source data comprising databases for ProteomDiscoverer, Kras/RAC2 kinetics, cleavage maps and PD2.1 result files have been submitted to Dryad under DOI:10.5061/dryad.jq2bvq88b

The following data sets were generated

Article and author information

Author details

  1. Gerald Willimsky

    Experimental and Translational Cancer Immunology, Institute of Immunology (Charité - Universitätsmedizin Berlin) and German Cancer Research Center (DKFZ Heidelberg), Berlin, Germany
    For correspondence
    gerald.willimsky@charite.de
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-9693-948X
  2. Christin Beier

    Biochemistry, Institute of Biochemistry (Charité - Universitätsmedizin Berlin), Berlin, Germany
    Competing interests
    The authors declare that no competing interests exist.
  3. Lena Immisch

    Experimental and Translational Cancer Immunology, Institute of Immunology (Charité - Universitätsmedizin Berlin) and German Cancer Research Center (DKFZ Heidelberg), Berlin, Germany
    Competing interests
    The authors declare that no competing interests exist.
  4. Georgios Papafotiou

    Experimental and Translational Cancer Immunology, Institute of Immunology (Charité - Universitätsmedizin Berlin) and German Cancer Research Center (DKFZ Heidelberg), Berlin, Germany
    Competing interests
    The authors declare that no competing interests exist.
  5. Vivian Scheuplein

    Molecular Immunology, Max-Delbrück Center for Molecular Medicine, Berlin, Germany
    Competing interests
    The authors declare that no competing interests exist.
  6. Andrean Goede

    Physiologie (, Institut für Physiologie (Charité - Universitätsmedizin Berlin), Berlin, Germany
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-9044-9869
  7. Hermann-Georg Holzhütter

    Biochemistry, Institute of Biochemistry (Charité - Universitätsmedizin Berlin), Berlin, Germany
    Competing interests
    The authors declare that no competing interests exist.
  8. Thomas Blankenstein

    Max Delbrück Center for Molecular Medicine in Helmholtz Association, Berlin, Germany
    Competing interests
    The authors declare that no competing interests exist.
  9. Peter M Kloetzel

    Institut für Biochemie, Charité - Universitätsmedizin Berlin, Berlin, Germany
    For correspondence
    p-m.kloetzel@charite.de
    Competing interests
    The authors declare that no competing interests exist.

Funding

Deutsche Forschungsgemeinschaft (SFB-TR36)

  • Gerald Willimsky
  • Thomas Blankenstein

Deutsche Krebshilfe (111546)

  • Gerald Willimsky

Berlin Institute of Health (CRG-1)

  • Thomas Blankenstein
  • Peter M Kloetzel

DKTK joint funding (NEO-ATT)

  • Gerald Willimsky

Berliner Krebsgesellschaft

  • Peter M Kloetzel

Helmholtz-Gemeinschaft, Zukunftsthema 'Immunology and Inflammation'

  • Gerald Willimsky
  • Thomas Blankenstein

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Ethics

Animal experimentation: All animal experiments were performed according to institutional and national guidelines and regulations. The experiments were approved by the governmental authority (Landesamt für Gesundheit und Soziales, Berlin, H0086/16).

Reviewing Editor

  1. Vincenzo Cerullo, University of Helsinki, Finland

Publication history

  1. Received: August 11, 2020
  2. Accepted: April 15, 2021
  3. Accepted Manuscript published: April 20, 2021 (version 1)
  4. Accepted Manuscript updated: April 22, 2021 (version 2)

Copyright

© 2021, Willimsky et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 442
    Page views
  • 84
    Downloads
  • 0
    Citations

Article citation count generated by polling the highest count across the following sources: Crossref, PubMed Central, Scopus.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Download citations (links to download the citations from this article in formats compatible with various reference manager tools)

Open citations (links to open the citations from this article in various online reference manager services)

  1. Further reading

Further reading

    1. Biochemistry and Chemical Biology
    Erich Stefan et al.
    Research Article Updated

    ATP-binding cassette (ABC) transporters constitute the largest family of primary active transporters involved in a multitude of physiological processes and human diseases. Despite considerable efforts, it remains unclear how ABC transporters harness the chemical energy of ATP to drive substrate transport across cell membranes. Here, by random nonstandard peptide integrated discovery (RaPID), we leveraged combinatorial macrocyclic peptides that target a heterodimeric ABC transport complex and explore fundamental principles of the substrate translocation cycle. High-affinity peptidic macrocycles bind conformationally selective and display potent multimode inhibitory effects. The macrocycles block the transporter either before or after unidirectional substrate export along a single conformational switch induced by ATP binding. Our study reveals mechanistic principles of ATP binding, conformational switching, and energy transduction for substrate transport of ABC export systems. We highlight the potential of de novo macrocycles as effective inhibitors for membrane proteins implicated in multidrug resistance, providing avenues for the next generation of pharmaceuticals.

    1. Biochemistry and Chemical Biology
    Qiang Liu et al.
    Research Article Updated

    The multimodal sensory channel transient receptor potential vanilloid-3 (TRPV3) is expressed in epidermal keratinocytes and implicated in chronic pruritus, allergy, and inflammation-related skin disorders. Gain-of-function mutations of TRPV3 cause hair growth disorders in mice and Olmsted syndrome in humans. Nevertheless, whether and how TRPV3 could be therapeutically targeted remains to be elucidated. We here report that mouse and human TRPV3 channel is targeted by the clinical medication dyclonine that exerts a potent inhibitory effect. Accordingly, dyclonine rescued cell death caused by gain-of-function TRPV3 mutations and suppressed pruritus symptoms in vivo in mouse model. At the single-channel level, dyclonine inhibited TRPV3 open probability but not the unitary conductance. By molecular simulations and mutagenesis, we further uncovered key residues in TRPV3 pore region that could toggle the inhibitory efficiency of dyclonine. The functional and mechanistic insights obtained on dyclonine-TRPV3 interaction will help to conceive therapeutics for skin inflammation.